The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus-Reference-Cited by-同舟云学术

The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus

Published:2015-08 Issue: Volume:20 Page:8-16
ISSN:1743-9191
Container-title:International Journal of Surgery
language:en
Short-container-title:International Journal of Surgery

Author:

Zhang Zong-ming,Lai Eric C.H.,Zhang Chong,Yu Hong-wei,Liu Zhuo,Wan Bo-jiang,Liu Li-min,Tian Zu-hao,Deng Hai,Sun Qiu-hong,Chen Xiao-ping

Funder

National Natural Science Foundation of China

Science and Technology Project of State Grid Corporation of China

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference64 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J. Clin.,2015

2. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis;Takizawa;Dig. Dis. Sci.,2007

3. An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus;Lin;J. Cancer Res. Clin. Oncol.,2011

4. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein;Cheng;Hepatogastroenterology,2007

5. A new classification for hepatocellular carcinoma portal vein tumor thrombus;Shi;J. Hepatobiliary Pancreat. Sci.,2011

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study;Frontiers in Oncology;2024-01-17

2. Advances in the Combined Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis;Advances in Clinical Medicine;2024

3. Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease;Journal of Hepatocellular Carcinoma;2024-01

4. A glycyrrhetinic acid-iridium(III) conjugate as a theranostic NIR probe for hepatocellular carcinoma with mitochondrial-targeting ability;European Journal of Medicinal Chemistry;2024-01